NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
14.54
-0.74 (-4.84%)
At close: Feb 11, 2026, 4:00 PM EST
14.56
+0.02 (0.14%)
After-hours: Feb 11, 2026, 4:32 PM EST
NeuroPace Revenue
NeuroPace had revenue of $27.35M in the quarter ending September 30, 2025, with 29.89% growth. This brings the company's revenue in the last twelve months to $94.86M, up 24.08% year-over-year. In the year 2024, NeuroPace had annual revenue of $79.91M with 22.14% growth.
Revenue (ttm)
$94.86M
Revenue Growth
+24.08%
P/S Ratio
4.89
Revenue / Employee
$453,895
Employees
209
Market Cap
484.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 79.91M | 14.49M | 22.14% |
| Dec 31, 2023 | 65.42M | 19.90M | 43.72% |
| Dec 31, 2022 | 45.52M | 337.00K | 0.75% |
| Dec 31, 2021 | 45.18M | 4.05M | 9.83% |
| Dec 31, 2020 | 41.14M | 4.17M | 11.27% |
| Dec 31, 2019 | 36.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Varex Imaging | 854.40M |
| Orthofix Medical | 818.06M |
| Bioventus | 563.83M |
| OrthoPediatrics | 227.41M |
| Cerus | 199.19M |
| Cytek Biosciences | 196.83M |
| Standard BioTools | 169.74M |
| Pacific Biosciences of California | 154.58M |
NPCE News
- 4 weeks ago - NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Business Wire
- 6 weeks ago - NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Business Wire
- 2 months ago - NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - Business Wire
- 2 months ago - NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire
- 2 months ago - NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services - Business Wire
- 3 months ago - NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript - Seeking Alpha